A Heartfelt Thank You to Our Research Supporters

From the bottom of our hearts, our lab wants to express our deepest thanks for the incredible support we receive. This funding is not just money – it’s the vital fuel that drives our mission to fight some of the toughest diseases affecting people everywhere, particularly deadly heart conditions and devastating neurological diseases like Alzheimer’s. Every experiment, every discovery we make in the lab is a step closer to understanding these illnesses and, ultimately, developing life-changing or life-saving treatments for patients and families facing these challenges. We are truly humbled and motivated by this responsibility.

None of our work would be possible without the steadfast commitment of major funding organizations. We are especially grateful to:

1. The American Heart Association (AHA): For their unwavering dedication to conquering heart disease and stroke, providing crucial support that has directly advanced our research on atherosclerosis and drug delivery to the cardiovascular system since 2012.

2. The National Institutes of Health (NIH): For their immense, foundational investment in biomedical research across the board, including vital grants supporting our work on heart disease, the development of nanomedicine and drug delivery approaches and our work on air pollution. Our lab was first funded by NIH in 2016.

3. The American Alzheimer’s Association: For their passionate focus on finding answers to Alzheimer’s and dementia, funding that has been instrumental in initiating our neurological disease research quest in 2021.

These organizations are far more than just funders – they are true champions of science. Their belief in researchers like us is what makes progress possible. To the AHA, NIH, American Alzheimer’s Association, and all who support them – thank you!!! Your partnership is invaluable. You enable our lab’s daily efforts, inspire our team, and give genuine hope for healthier futures. We are profoundly grateful for your trust and your shared commitment to making a real difference through research.

Below, we highlight the projects that were recently funded in our lab.

Non-racemic metabolic biomaterials for HFpEF

Major Goals: This proposal will develop a new class of biomaterial-based immunomodulators which work via targeted suppression of specific immune cells in heart failure with preserved ejection fraction (HFpEF)

Project Number: R01 HL155450-01A1

Name of PD/PI: Andrei Maiseyeu (PI)

Source of Support: NIH

Targets and targeting of immunometabolism in chronic PM2.5 exposure

Major Goals: We will characterize air pollution-induced changes in inflammation resolution pathways and determine to what extent these pathways overlap with dietary manipulation.

Project Number: R01 ES033670-01

Name of PD/PI: Andrei Maiseyeu (PI), Sanjay Rajagopalan (co-PI)

Source of Support: NIH

Targeting genomic instability in Alzheimer’s disease with HDAC activator

Major Goals: In this proposal we will test a new nanomaterial that exhibits potent enhancing activity.

Project Number: Grant 924642

Name of PD/PI: Andrei Maiseyeu (PI)

Source of Support: Alzheimer’s Association

Targeting remnant cholesterol through epigenetic modulation of ApoC-III

Major Goals: This proposal aims to uncover the role of itaconate axis in cardiovascular disease, specifically, how itaconate, an endogenous immune cell-derived metabolite, may regulate remnant cholesterol, a category of triglyceride-rich lipoproteins responsible for significant residual risk in atherosclerosis.

Project Number: 24TPA1304062

Name of PD/PI: Andrei Maiseyeu (PI)

Source of Support: American Heart Association

Engineered polymeric adjuvants for heart-redirected targeting

Major Goals: In this project, we aim to develop and improve the delivery of various therapies, including adeno-associated viral (AAV) and nanoparticle (NP) gene therapy to the heart.

Project Number: 1R01HL166241-01

Name of PD/PI: Andrei Maiseyeu (PI)

Source of Support: NIH